Compare GKOS & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GKOS | RDY |
|---|---|---|
| Founded | 1998 | 1984 |
| Country | United States | India |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 9.9B |
| IPO Year | 2015 | 2001 |
| Metric | GKOS | RDY |
|---|---|---|
| Price | $238.12 | $14.84 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 5 |
| Target Price | ★ $243.85 | $14.79 |
| AVG Volume (30 Days) | 1.5M | ★ 2.3M |
| Earning Date | 10-28-2026 | 10-23-2026 |
| Dividend Yield | N/A | ★ 0.43% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $507,442,000.00 | N/A |
| Revenue This Year | $53.82 | $4.58 |
| Revenue Next Year | $28.56 | $11.95 |
| P/E Ratio | ★ N/A | $18.67 |
| Revenue Growth | ★ 32.33 | N/A |
| 52 Week Low | $93.78 | $11.36 |
| 52 Week High | $255.19 | $15.67 |
| Indicator | GKOS | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 59.90 | 69.00 |
| Support Level | $147.72 | $12.91 |
| Resistance Level | $255.19 | $15.08 |
| Average True Range (ATR) | 11.84 | 0.25 |
| MACD | -1.49 | -0.03 |
| Stochastic Oscillator | 43.31 | 82.52 |
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.